| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
IL-17
Interleukin-17 (IL-17), a pro-inflammatory cytokine family (primarily IL-17A) produced by Th17 cells and other immune cells, that drives inflammation, neutrophil recruitment, and the production of other inflammatory cytokines and chemokines in autoimmune diseases and cancer. |
|---|---|
| ln Vitro |
No specific in vitro activity data (e.g., IC50 or pIC50) are publicly available for IL-17 modulator 3. As an IL-17 modulator, it is expected to inhibit IL-17 signaling in cell-based assays, blocking IL-17-induced production of CXCL8, IL-6, and CCL20 in fibroblasts, keratinocytes, or epithelial cells.
|
| ln Vivo |
No published in vivo data. As an IL-17 modulator, it would be expected to reduce disease severity in animal models of autoimmune disease (e.g., psoriasis, arthritis) and inflammation, though this remains to be validated for this specific compound.
|
| Enzyme Assay |
A biochemical binding assay (e.g., AlphaLISA, TR-FRET, or ELISA) is used to assess IL-17 modulation. Recombinant human IL-17A is incubated with a labeled IL-17 receptor or anti-IL-17 antibody in the presence of serially diluted modulator 3 (0.1-1000 nM). The assay signal is measured to calculate the half-maximal inhibitory concentration (IC50).
|
| Cell Assay |
For in vitro cellular assays, IL-17A-responsive cell lines (e.g., HT-29, human dermal fibroblasts, or HaCaT keratinocytes) are seeded in 96-well plates. Cells are pre-incubated with serially diluted modulator 3 (0.1-1000 nM) for 1 hour, then stimulated with recombinant human IL-17A (10 ng/mL) for 24 hours. Supernatants are collected, and CXCL8 (IL-8) or CCL20 levels are measured by ELISA. The IC50 is calculated from the dose-response curve.
|
| Animal Protocol |
No published in vivo data. For research use, the imiquimod (IMQ)-induced psoriasis-like mouse model is used. BALB/c mice are treated topically with IMQ cream on the shaved back for 5-7 days. IL-17 modulator 3 is administered orally or intraperitoneally at 10-50 mg/kg daily. PASI scores (erythema, scaling, thickness) are recorded daily. On day 5-7, skin biopsies are taken for histopathological analysis and cytokine measurement by qPCR or ELISA.
|
| ADME/Pharmacokinetics |
IL-17 modulator 3 has a molecular weight of 579.73 g/mol and a formula of C31H45N7O4. DMSO solubility is high (≥50 mg/mL). Detailed PK parameters (e.g., half-life, oral bioavailability) are not publicly available; as a small molecule, PK properties will depend on formulation and administration route, with oral bioavailability likely moderate.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data are not publicly available. As a small-molecule IL-17 modulator, potential toxicities may include increased susceptibility to infections (consistent with IL-17 blockade) and gastrointestinal disturbances. No severe toxicities have been reported in research models.
|
| References | |
| Additional Infomation |
IL-17 modulator 3 is a research compound not approved for clinical use. It is extracted from patent US20200247785A1 (IL-17 ligands and uses thereof) and is used to study the role of IL-17 in inflammation, cancer, and autoimmune diseases. It is a tool compound for investigating the therapeutic potential of small-molecule IL-17 modulation as an alternative to injectable biologics.
|
| Molecular Formula |
C31H45N7O4
|
|---|---|
| Molecular Weight |
579.73
|
| Exact Mass |
579.353
|
| CAS # |
2467731-88-8
|
| PubChem CID |
154618162
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
42
|
| Complexity |
909
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
N1(C)C(C(N[C@@H](C2CCCCCC2)C(NC2=CC=C(C[C@@H](NC(=O)CC)C(N3CCN(C)CC3)=O)C=C2)=O)=O)=CC=N1
|
| InChi Key |
IIGKTWLHJSIYEK-NAKRPHOHSA-N
|
| InChi Code |
InChI=1S/C31H45N7O4/c1-4-27(39)34-25(31(42)38-19-17-36(2)18-20-38)21-22-11-13-24(14-12-22)33-30(41)28(23-9-7-5-6-8-10-23)35-29(40)26-15-16-32-37(26)3/h11-16,23,25,28H,4-10,17-21H2,1-3H3,(H,33,41)(H,34,39)(H,35,40)/t25-,28+/m1/s1
|
| Chemical Name |
N-[(1S)-1-cycloheptyl-2-[4-[(2R)-3-(4-methylpiperazin-1-yl)-3-oxo-2-(propanoylamino)propyl]anilino]-2-oxoethyl]-2-methylpyrazole-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (172.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7249 mL | 8.6247 mL | 17.2494 mL | |
| 5 mM | 0.3450 mL | 1.7249 mL | 3.4499 mL | |
| 10 mM | 0.1725 mL | 0.8625 mL | 1.7249 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
